Cannara Biotech Future Growth
Future criteria checks 3/6
Cannara Biotech is forecast to grow earnings and revenue by 14.3% and 13.8% per annum respectively while EPS is expected to grow by 14.6% per annum.
Key information
14.3%
Earnings growth rate
14.57%
EPS growth rate
| Personal Products earnings growth | 29.9% |
| Revenue growth rate | 13.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 29 Jul 2025 |
Recent future growth updates
No updates
Recent updates
Investors Still Aren't Entirely Convinced By Cannara Biotech Inc.'s (CVE:LOVE) Earnings Despite 27% Price Jump
Jul 05
A Piece Of The Puzzle Missing From Cannara Biotech Inc.'s (CVE:LOVE) 26% Share Price Climb
May 09There May Be Underlying Issues With The Quality Of Cannara Biotech's (CVE:LOVE) Earnings
May 07We Like These Underlying Return On Capital Trends At Cannara Biotech (CVE:LOVE)
Apr 07A Piece Of The Puzzle Missing From Cannara Biotech Inc.'s (CVE:LOVE) 40% Share Price Climb
Jan 29Returns At Cannara Biotech (CVE:LOVE) Are On The Way Up
Jan 03Benign Growth For Cannara Biotech Inc. (CVE:LOVE) Underpins Its Share Price
Nov 26These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt Extensively
Oct 29Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With Earnings
Aug 22Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To Continue
Aug 21Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?
Jul 14Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares
May 09Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today
Feb 28Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking
Jan 24Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point
Dec 18Is Cannara Biotech (CVE:LOVE) A Risky Investment?
Jul 29Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price
Apr 10Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden
Jan 26Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear
Jan 27Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet
Dec 10Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt
Mar 16Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?
Jan 22
Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?
Dec 18Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 8/31/2027 | 137 | 17 | N/A | 23 | 1 |
| 8/31/2026 | 121 | 15 | N/A | 23 | 1 |
| 8/31/2025 | 104 | 9 | N/A | 19 | 1 |
| 5/31/2025 | 102 | 16 | 15 | 20 | N/A |
| 2/28/2025 | 94 | 13 | 5 | 11 | N/A |
| 11/30/2024 | 87 | 7 | 10 | 16 | N/A |
| 8/31/2024 | 82 | 6 | 3 | 11 | N/A |
| 5/31/2024 | 77 | 5 | 2 | 10 | N/A |
| 2/29/2024 | 73 | 6 | 1 | 9 | N/A |
| 11/30/2023 | 66 | 9 | -2 | 7 | N/A |
| 8/31/2023 | 57 | 7 | -4 | 6 | N/A |
| 5/31/2023 | 51 | 5 | -13 | 0 | N/A |
| 2/28/2023 | 45 | 3 | -18 | -5 | N/A |
| 11/30/2022 | 40 | 3 | -22 | -7 | N/A |
| 8/31/2022 | 36 | 2 | -22 | -6 | N/A |
| 5/31/2022 | 30 | 1 | -41 | -2 | N/A |
| 2/28/2022 | 27 | 1 | -36 | 2 | N/A |
| 11/30/2021 | 22 | 1 | -32 | 2 | N/A |
| 8/31/2021 | 17 | -2 | -33 | -2 | N/A |
| 5/31/2021 | 11 | -7 | -9 | -6 | N/A |
| 2/28/2021 | 5 | -11 | -13 | -10 | N/A |
| 11/30/2020 | 3 | -13 | -14 | -9 | N/A |
| 8/31/2020 | 3 | -12 | -19 | -9 | N/A |
| 5/31/2020 | 3 | -12 | -22 | -8 | N/A |
| 2/29/2020 | 2 | -12 | -30 | -9 | N/A |
| 11/30/2019 | 2 | -13 | -34 | -9 | N/A |
| 8/31/2019 | 2 | -12 | -31 | -7 | N/A |
| 8/31/2018 | 1 | -4 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LOVE's forecast earnings growth (14.3% per year) is above the savings rate (2.6%).
Earnings vs Market: LOVE's earnings (14.3% per year) are forecast to grow faster than the Canadian market (11.1% per year).
High Growth Earnings: LOVE's earnings are forecast to grow, but not significantly.
Revenue vs Market: LOVE's revenue (13.8% per year) is forecast to grow faster than the Canadian market (3.9% per year).
High Growth Revenue: LOVE's revenue (13.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LOVE's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/21 19:59 |
| End of Day Share Price | 2025/09/19 00:00 |
| Earnings | 2025/05/31 |
| Annual Earnings | 2024/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cannara Biotech Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Greg McLeish | Research Capital Corporation |